Search

Displaying results 5591 - 5600 of 10000 in total
  1. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    It is being developed by Vitae Pharmaceuticals.

  2. Drug

    Ocaperidone

    go.drugbank.com/drugs/DB06229
    Experimental

  3. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    It has since been demonstrated that the agent possesses activity against amoebas and yaws. … Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol.

  4. Drug

    Phosphoaminophosphonic acid guanylate ester

    go.drugbank.com/drugs/DB02082
    Experimental

    A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.

  5. Drug

    (1R,2S)-2-Phenylcyclopropanaminium

    go.drugbank.com/drugs/DB02665
    Experimental

    This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders.

  6. Drug

    Zebularine

    go.drugbank.com/drugs/DB03068
    Experimental

    Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo. … It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates.

  7. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    It provides patients with long term therapeutic benefit from a single administration rather than multiple injections.

  8. Drug

    Galiximab

    go.drugbank.com/drugs/DB04901
    Investigational

    Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

  9. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753] … Pimicotinib is under investigation in clinical trial NCT05804045 (Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)).

    Synonyms: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-, 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamide
  10. Drug

    CoronaVac

    go.drugbank.com/drugs/DB15806
    Investigational

    It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone[A219481;A219758]. … In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the rhesus macaque.